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This study investigates a method to predict medical outcome of cholinesterase inhibitors in patients with Alzheimer’s disease (AD)
and vascular dementia (VaD).VanGool predicts that patientswith cholinergic deficit symptomswill benefit from treatmentwhereas
patients without will experience side effects because of overstimulation of the cholinergic system. We predicted that AD and VaD
patients with a longer RT experience fewer side effects than patients with a faster response and that VaD patients have a longer RT
than AD patients. A number of 71 patients with AD or VaD diagnosis were included. A sustained attention task was administered,
as well as the MMSE and a questionnaire about side effects. Results indicated that VaD patients with a longer RT reported fewer
side effects. Furthermore, patients with VaD had a longer RT than patients with AD. MMSE was negatively correlated with RT in
the VaD group. Thus, the performance on the attention task seems associated with suffering from side effects and thus tends to
predict medical outcome in VaD, but not in AD. Perhaps this attention task was not sensitive enough to measure cholinergic deficit
symptoms in AD patients. Furthermore, different doses of medication might confound the effect for the AD group.
1. Introduction
According to the National Health Service (NHS) in the
United Kingdom one in three elderly people will develop
dementia, of which two thirds are women. The total number
is rising as people tend to live longer. The most common
types of dementia are Alzheimer’s disease (AD) and vascular
dementia (VaD). The Diagnostic and Statistical Manual of
Mental Disorders (DSM) IV-TR characterizes both AD and
VaD as multiple cognitive deficits manifested by memory
impairment and one (or more) cognitive disturbances, like
aphasia, apraxia, agnosia, or disturbances in executive func-
tioning [1]. In AD these cognitive deficits should each cause
significant impairment in social/occupational functioning
and show a decline compared to previous functioning levels
which should include a gradual onset and continuing decline.
The addition for VaD is that there should be evidence of focal
neurological signs and symptoms or neuroimaging evidence
indicating cerebrovascular diseases that are judged to be
etiologically related to the disturbance.
There is evidence for signs of degeneration of neurons
in the cholinergic system in VaD and AD [2, 3], 40% loss
of cholinergic neurons in VaD and even 70% in AD cases
[4]. Deficits in the cholinergic system are not exclusively
restricted to dementia but are also known in other dis-
orders like Lewybodies dementia, Parkinson’s disease, and
Down’s syndrome [5]. Deficits in the cholinergic system are
characterized by symptoms like lack of attention, problems
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with concentration, and decreased ability to detect and select
relevant stimuli leading to restlessness, anxiety, and confu-
sion [5]. Because of decreased connection with the outside
world, delusions and hallucinations often occur. Therefore,
performance on cognitive tests is usually abnormal although
there is no focal cortical disorder present [5].
At this moment, dementia cannot be cured. However,
medication is given to delay cognitive deterioration, which
might postpone moving patients into nursing homes [6].
Cholinesterase inhibitors (ChEIs) are commonly prescribed
to suppress the symptoms as a decrease in cholinergic neu-
rotransmission might lead to the cognitive and behavioural
disturbances in dementia, particularly in AD.This treatment
can cause severe side effects, like gastrointestinal problems,
insomnia, anorexia, nausea, diarrhea, vomiting [7, 8], alter-
ation in the cardiovascular system [7, 9], and an increased
risk of death (through cardiovascular problems) [7, 8]. This
raises the question if there is a method to predict the efficacy
of medication and its side effects.
Theoretical Framework. The hypothesis of Van Gool [5]
suggests that in particular dementia patients who show
cholinergic deficit symptomswill benefit fromChEIs whereas
dementia patients without these symptoms will suffer from
severe side effects because of overstimulation of the cholin-
ergic system. Patients with cholinergic deficit symptoms have
attention problems and thus will have a longer reaction time
(RT). The following three hypotheses will be tested. (1) AD
patients with a longer RT on the attention task will benefit
more from treatment than patients with an average or faster
RT and will therefore experience fewer side effects. (2) VaD
patients with a longer RT on the attention task will benefit
more from treatment than patients with an average or faster
RT (and should experience less side effects). (3) As the task
measures sustained attention, which is impaired at an early
stage of VaD but usually preserved in AD [10, 11], it is
predicted that VaD patients have a longer RT on the attention
task than AD patients. It is possible that cholinergic deficits
are an extra factor in a longer RT; however, the main reason
that RT is longer in vascular dementia than in Alzheimer’s
disease in general is because of other reasons. White matter
and periventricular hyperintensities aremost severe in vascu-
lar dementia versus other dementia types such as Alzheimer’s
disease [12]. Such abnormalities are related to deficits in
cognition, like slowing ofmental processing speed, decreased
working memory, and impairment of abstract reasoning [13].
2. Method
This study included 421 patients with the diagnosis AD (𝑛 =
325; males = 151; females = 174) or VaD (𝑛 = 96; males =
49; females = 47) of which 111 participants performed the
attention task before the start of treatment of ChEIs (Reminyl
and Exelon). Medications included 3 different maximum
doses of Reminyl (8/16/24) and 2 of Exelon (4.6/9.5). Patients
were treated by a dose chosen by the geriatricians, which was
adapted during the treatment period which makes it hard
to account for. Neither plasma levels nor compliance was
measured. Residual analyses revealed that 3 (2 AD; 1 VaD) of
111 participants (AD = 88, VaD = 23) had a mean RT score
whichwas 3 ormore standard deviations (SD) from themean.
This finding in combination with the observations of the test
leader suggested that the patients might not have understood
the instructions, and therefore these subjects were excluded
from the analyses.
Participants had a diagnosis of AD orVaD in line with the
DSM-IV criteria. They were recruited in the Albert Schweit-
zer Hospital in Dordrecht, the Netherlands. Clinical diag-
noses were made by a senior geriatrician. Patients with delir-
ium or patients who were immobile did not participate in
this study. All participants gave written informed consent
after having been informed about the purpose of the study
research. The study has approval of the medical ethical
committee of the Albert Schweitzer Hospital. In this study,
an attention task was administered to measure sustained
attention before medication was given. In addition, theMini-
Mental State Examination (MMSE) and a short composed
questionnaire measuring adverse side effects of the treatment
with ChEIs (Appendix B) were administered.
2.1. Attention Task. Participants were asked to press a button
when one of a total of 30 stimuli was presented on the
screen. The time it took for the participant to react to each
stimulus and the summation of the total RT was registered in
milliseconds. The task took less than two minutes. The first
5 trials were considered as practice tasks and therefore not
included in the analyses. Requirements of participating were
that the patient could be seated behind a desk and was able to
understand the instructions. Before performing the attention
task the participant was verbally instructed to react whenever
the white figure would turn into orange. As soon as the color
turned orange the timer started measuring the time until the
participant reacted to the stimulus in milliseconds.
2.2. Mini-Mental State Examination (MMSE). The Mini-
Mental State Examination (Appendix A) is the most com-
monly used screening test for the evaluation of cognitive
impairment. During this examination orientation, recall,
attention, recording capacity, language, and constructive
praxis were tested [14].TheMMSE can be used to estimate the
severity of dementia, whether there is no dementia present
(24–30), mild dementia (20–23), moderate (10–19), or a
severe case of dementia (0–9) [15].
2.3. Questionnaire. The questionnaire (Appendix B) con-
sisted of six dichotomous questions (yes, no), one question
with three options (none, doubt, and good) and two open
questions about the medication and the side effects. Side
effects were measured through questioning by geriatricians
of any additional side effects since the start of medication
(yes/no). In addition, geriatricians reported what other side
effects there were, not the severity. Examples of side effects
are, but not limited to, dizziness, nausea, and agitation.
2.4. Statistical Analyses. The program SPSS version 22 was
used for the statistical analyses. The study had a quasiex-
perimental design, with two patient groups (AD and VaD)
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Table 1: Demographic data and comparisons between groups on the task and questionnaire.
AD VaD df 𝐹-value 𝑝-value
Age (years) 77.93 ± 6.552 78.93 ± 7.8 70 .242 .624
Gender M : F 27 : 30 9 : 5 70 1.274 .263
MMSE 20.54 ± 3.928 21.29 ± 4.250 70 .388 .535
Number of side effects .656 ± .701 .600 ± .894 63 3.023 .087
Occurrence of side effects 25 : 27 4 : 8 63 .840 .363
Mean RT (ms) 829.840 ± 445.751 1099.162 ± 519.219 70 3.845 .027
Mean ± SD, MMSE =Mini-Mental Stage Examination, RT = reaction time, AD = Alzheimer’s disease, VaD = vascular dementia, and df = degrees of freedom.
who completed the attention task,MMSE, and questionnaire.
An independent 𝑡-test was used to test a difference between
the mean RT of both patient groups, controlling for unequal
variances. One-way analyses of variance (ANOVAs) were
performed to test the differences in age, gender, MMSE,
number, and occurrence of side effects, between the patient
groups. Subsequent ANOVAs and regression analyses were
used to evaluate if RT differed between the side effect groups,
for the total sample and separate patient groups. Further-
more, an additional regression analysis was used to test for
a difference in RT between patients with and without side
effects, for the total group and separate patient groups. In
addition, Pearson correlation between MMSE score and RT
was calculated using “Bivariate correlation,” for the total
group as well as separately for AD and VaD.
3. Results
3.1. Differences between AD and VaD. In this study data
from 71 of the 111 participants were included in the analyses.
These were the participants who fulfilled the requirements
of (1) performing the attention task before taking Exelon or
Reminyl, (2) scoring above MMSE score 12, and (3) having a
mean RT not deviating more than 3 SD from the mean. The
first 5 trials were considered to be practice trials. Therefore,
mean RT was calculated by averaging all trials excluding the
first 5 trials.
Patient groups tended to differ on the number of side
effects (Table 1) as AD patients would experience more side
effects than VaD patients. Patient groups did not significantly
differ on age, gender, MMSE score, or occurrence of side
effects (yes/no). An independent 𝑡-test revealed a significant
difference between patient groups on mean RT, when only
trial scores were included that deviated less than 3 SD from
the mean (𝑝 [1-tailed] = .027, 𝑝 variances unequal [1-tailed] =
.045); as predicted VaD patients had a longer RT than AD
patients (Figure 1).
3.2. Relation between the Number of Side Effects and RT.
To test the relation between the number of side effects and
RT, a regression analysis was performed, controlling for age,
gender, MMSE score, and diagnosis. We excluded data from
subjects whenmeanRT scores weremore than 3 SDs from the
sample mean.The correlation betweenmean RT and number
Table 2: Results ANOVA mean RT by side effects.
Sample IV 𝐹 𝑝
Total group Number of side effects .423 .737
Total group Occurrence of side effects .000 .998
AD Number of side effects .471 .704
VaD Number of side effects 1.33 .331
AD Occurrence of side effects .023 .881
VaD Occurrence of side effects .319 .585
IV = independent variable, RT = reaction time, AD = Alzheimer’s disease,

















Figure 1: Mean RT (𝑧-score) and SD bars for AD and VaD patients.
of side effects was not significant (𝑟 = −.041, 𝑝 [1-tailed] =
.188) when calculated for the total group of subjects. In con-
trast, (bivariate) correlation analyses performed separately
in each patient group revealed a different direction of the
correlations between the mean RT and the number of side
effects; namely non-significant for the AD (𝑟 = .048, 𝑝 [1-
tailed] = .37) versus significant for the VaD group (𝑟 = −.445,
𝑝 [1-tailed] = .037).
A one-way ANOVA with “number of side effects” as
independent variable in the total group showed that “number
of side effects” had no effect on the mean RT (Tables 2 and 3).
Another ANOVAwas performed, using the grouped variable






















Figure 2: Occurrence of side effects versus mean RT trial (ms), for
AD and VaD.
Table 3: Number of side effects with associated mean RT.
Number of
side effects Total AD 𝑛 VaD 𝑛
Mean RT
(ms)
0 682.914 666.391 25 941.340 4
1 809.126 632.898 16 1156.973 3
2 723.281 794.075 10 599.493 3
3 441.867 396.320 1 464.640 2
RT = reaction time, AD=Alzheimer’s disease, VaD = vascular dementia, and
𝑛 = number of participants.
Table 4: Occurrence of side effects with the accompanied mean RT.
Occurrence
of side effects Total AD 𝑛 VaD 𝑛
Mean RT
(ms)
No 704.3149 666.3909 25 941.3400 4
Yes 704.6317 683.8307 27 774.8350 8
RT = reaction time, AD=Alzheimer’s disease, VaD = vascular dementia, and
𝑛 = number of participants.
“occurrence of side effects (yes/no)” instead of the “number
of side effects”, which also showed no effect on the mean RT
(Tables 2 and 4). Splitting up the total group in VaD and AD
groups to find an effect for the number of side effects on the
mean RT, did not lead to significant results either (Table 2).
These results are probably due to the magnitude of the SD;
see Figure 2.
In summary, despite the nonsignificant results of the
ANOVA, a significant negative correlation was observed for
the VaD group between the number of side effects and the
mean RT. This correlation indicated a longer RT when a
patient did not or experienced less side effects compared to
when he/she experienced more side effects (Table 3). There
appeared to be no such trend for the number of side effects
and RT for the total group as well as for the AD group; see
Table 3.
3.3. Relation MMSE Score and RT. Correlation analyses
calculated for the total sample showed a nonsignificant
correlation between RT and the MMSE score, 𝑟 = −.172,
𝑝 = .151 (Table 5). Splitting the groups resulted in different
findings. For the AD group, theMMSE did not correlate with
Table 5: Overview of correlation analyses with MMSE score and
mean RT.







RT = reaction time, AD = Alzheimer’s disease, VaD = vascular dementia, 𝑟 =
correlation, and 𝑝 = 𝑝 value.
the mean RT of the sustained attention task as 𝑟 did not
suggest a strong positive or negative correlation, 𝑟 = −.035,
𝑝 = .796, (Table 5). For the VaD group, the MMSE negatively
correlated with the mean RT (𝑟 = −.738, 𝑝 = .003)
(Table 5). In addition, the value of 𝑟 indicates a strong neg-
ative correlation between MMSE and RT, a longer RT when
the patient had a lower (worse) score on the MMSE.
4. Conclusions
4.1. Hypotheses. The aim of this study was to test the hypoth-
esis of VanGool in order to predict the side effects of ChEIs in
ADandVaDpatients.Thehypothesis stated that patientswith
dementia with cholinergic deficit symptoms will benefit from
ChEI medication whereas patients without these symptoms
will suffer from side effects because of overstimulation of
the cholinergic system. As patients with cholinergic deficit
symptoms have attention problems, they will have a longer
RT, leading to the following 3 hypotheses: (1) AD patients
with a longer RT than average on the attention task will
benefit more from treatment than patients with an average
or faster one and thus should show less side effects, (2)
VaD patients with a longer RT than average on the attention
task will benefit more from treatment than patients with an
average or faster one and thus should show fewer side effects,
and (3) as the task measures sustained attention which is
impaired at an early stage of VaDbut usually preserved inAD,
it is predicted that VaD patients will have a longer RT on the
attention task than AD patients. Hypothesis 1 can be rejected
as correlation analyses revealed no specific direction or
significant correlation between the mean RT and the number
of side effects for AD patients, as well as for the mean RT and
the occurrence of side effects for the AD group. Furthermore,
a one-wayANOVA confirmed these results. Hypothesis 2 was
confirmed. Correlation analyses indicated a negative correla-
tion between the mean RT and the number of side effects for
the VaD group. Nevertheless, ANOVA results are nonsignifi-
cant, which is probably due to the magnitude of the SD of the
RT scores. Hypothesis 3 was also confirmed using the mean
RT that is corrected for deviations of 3 or more SD from the
mean, 𝑝 < .027, which is in line with the previous research.
4.2. MMSE and RT. In addition, to validate the attention
task a correlation analysis was performed between RT and
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the MMSE score, resulting in nonsignificant results. Splitting
up the sample in AD and VaD groups showed that although
the MMSE score did not correlate with the mean RT for the
AD group, it did correlate negatively for the VaD group. In
other words, a lower (worse) MMSE score was related to a
longer RT for the VaD group. This result might be explained
by the notion that VaD is associated with white matter loss
and more severe periventricular hyperintensities [12], which
are related to slowing of mental processing speed, as well as
other deficits in cognition [13]. These lead to a longer RT as
well as to more general cognitive problems compared with
AD patients. This is in line with the trend that VaD patients
experience more side effects than AD patients.
4.3. Summary. Thus, the attention task tends to predict the
side effects in VaD, but not in the AD group. Perhaps the
task is only a valid method to predict side effects in patients
with VaD and not in AD as it might not be subtle enough to
measure the cholinergic deficit symptoms in patients without
general cognitive deficits. However, patient groups were not
equal in this study, andmedication doses varied, whichmight
have undermined the effect for AD. More research is needed
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Other side effects Yes/no
What other side effects Open question
Satisfaction medication Negative/doubt/positive
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